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BACKGROUND AND AIMS: Pancreatic adenocarcinoma is a deadly disease characterized bymetastatic progression and
resistance to conventional therapeutics.MutationofKRAS is themost frequent early event in pancreatic tumor progression.
AKT isoforms are frequently activated in pancreatic cancer, and reports have implicated hyperactivation of AKT1, aswell as
AKT2, in pancreatic tumor formation. The objective here is to delineate the role of AKT in facilitating in vivopancreatic tumor
progression in the context of KRASmutation and predisposition to pancreatic cancer.METHODS:MicewithAkt1 and KRas
mutant alleles expressed using the pancreas Pdx promoter were mated to characterize the incidence and frequency of
histologic andgenetic alterations known tooccur commonly inhumanpancreaticductal adenocarcinoma.RESULTS:Active
Akt1 (Akt1Myr, containing a myristoylation sequence) cooperated with active mutant KRasG12D to accelerate pancreatic
carcinoma onset and progression and increase phosphorylation of downstream effectors in the Akt pathway. Mucin and
smooth muscle actin expression was found in and around pancreatic intraepithelial neoplasms (PanINs), and accelerated
time to metastasis was found in Akt1Myr/KRasG12D mice. CONCLUSIONS: In contrast to prior reports of pancreatic KRas
mutantmicematedwithmice deficient for various tumor suppressor genes, which resulted in aggressive diseasewithin a
fewmonths of age, Akt1Myr/KRasG12Dmice enabled the study of PanINs and spontaneous pancreatic transformationmore
characteristic of human pancreatic progression in elderly individuals. The Akt1Myr/KRasG12D model holds promise for
delineating the tumor biology and biomarkers critical for understanding their cooperation in cancer oncogenesis and future
targeting in therapeutic strategies.
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Activating KRAS mutations are present in virtually all human
pancreatic adenocarcinomas and occur with increasing frequen-
cy in later stage pancreatic intraepithelial neoplasia (PanIN)
lesions [1,2]. To date, the model that most faithfully
recapitulates human PanIN development and its early progres-
sion is a mouse model that expresses a Cre-activated KRas allele
knocked into the endogenous KRas locus [3] when crossed with
mice expressing a Pdx1-Cre recombinase transgene promoter
[4]. Oncogenic KRasG12D in the progeny of the Cre matings
developed PanINs within a few months, with activation of the
Notch pathway and overexpression of COX-2 and MMP-7 [5].
This model thus offered the first recapitulation of human
PanIN lesions, with low incidence of progression to pancreatic
adenocarcinoma [5].
176 Akt1 and KRas cooperate in vivo to accelerate PDAC Albury et al. Neoplasia Vol. 17, No. 2, 2015In comparison, Pdx-Cre;Ptenlox/lox mice with pancreatic knockout of
Pten display rapid progression of pancreatic ductal metaplasia, development
of PanINs, and low frequency of malignant transformation [6]. Under
normal conditions,mouse andhumanPTENfunctions as a dual-specificity
protein phosphatase and a lipid phosphatase. Because PTEN modulates
phosphatidylinositol 3-kinase (PI3K)–AKT signaling, loss of PTEN tumor
suppressor function in pancreatic tumor progression further implicates the
importance of AKT signaling in pancreatic pathogenesis.
Othermousemodels of pancreatic cancer have been developed to study
components of the PI3K/PTEN/AKT signaling pathway. A previous
study analyzed constitutively active mutant AKT1 under control of Pdx-
Cre, elastase-Cre, and rat insulin promoter-2–Cre expression [7].
Interestingly, premalignant lesions and acinar tumors were observed
when expression was driven by Pdx-Cre. Constitutively active myristoy-
lated (Myr) Akt1 under rat insulin promoter-2 was also shown to result in
malignant transformation of islet cells to develop islet cell carcinomas [8].
Most recently, a mouse model with a constitutively activated catalytic
subunit of PI3K was used to study the importance of PI3K signaling in
Kras-driven pancreatic ductal adenocarcinoma (PDAC) initiation and
maintenance [9] and the requirement of 3-phosphoinositide dependent
protein kinase 1 (PDK1) signaling for KRas pancreatic cell plasticity
and cancer. Of relevance to human pancreatic cancer, earlier reports
showed amplification and protein overexpression of AKT2 in human
pancreatic cell lines [10], and both AKT1 and AKT2 were found in
human PDACs and in metastases [11]. AKT alterations are among the
most commonly activated oncogenic changes in solid tumors and
activation of AKT isoforms is frequently attributed to down-regulation of
PTEN tumor suppressor or activation of upstream signaling components
(activating PI3Kmutations or activating growth factor receptors). A prior
study, using immunohistochemistry and tissue microarrays, revealed
that 34 of 133 (~25%) stage II PDACs exhibited loss of PTEN
expression [12]. Haplo-insufficiency and occasional homozygous loss of
PTEN have also been found in human PDACs [11]. Overall, the data
support a dosage-dependent role for mouse and human PTEN and in the
activation of downstream AKT [13].
Herein, we report the first evidence describing the contribution of
constitutively active myristoylated Akt1 in vivo to pancreatic ductal tumor
progressionusing genetically defined transgenicmodels to delineate potential
cooperation withPdx-regulated expression of KRasG12D. Collectively, these
studies provide insights regarding the pathogenic implication of Akt
perturbations in combination with KRas oncogenic mutations to accelerate
pancreatic progression toward the development of invasive PDAC. In
addition, we propose that this dual oncogene model may offer long-term
preclinical utility for testing of novel therapeutic strategies against pancreatic
tumor progression and an opportunity to intervene before extensive
desmoplastic fibrosis and irreversible tissue remodeling, which is a
confounding problem in the treatment of late-stage pancreatic disease.
Material and Methods
Genetically Engineered Mice
Animal care and use was at Association for Assessment and
Accreditation of Laboratory Animal Care International (AAALAC)-
accredited facilities. Protocols were approved by Institutional Animal
Care and Use Committees at each respective institution and were
compliant with NIH guidelines. Pdx-tTAmice in an FVB/n background
[14] were mated withTetO-MyrAkt1mice in a C57Bl/6 to generate Pdx-
tTA;TetO-MyrAkt1 mice (Figure S1). LSL-KRasG12D [3] in a 129Sv/J
background and Pdx-Cre [4] mice in a C57Bl/6 were mated to generatePdx-Cre;LSL-KRasG12D mice. The progeny were mated to generate litters
that were genotyped usingDNAextracted from tail snips (WizardGenomic
DNA Kit; Promega, Madison, WI) and were monitored for the tumor
latency study. In total, 29 Pdx-Cre;LSL-KRasG12D (designated KRasG12D
mice) and 30 Pdx-tTA;TetO-MyrAkt1 (designated Akt1Myr/KRasG12D
mice) were followed. Animals were housed until times outlined and then
killed in accordance with American Veterinary Medical Association
guidelines. Single Nucleotide Polymorphism (SNP) analysis performed by
Charles River Laboratories International (Wilmington, MA) on randomly
selected mice that were re-derived for the b1 year analysis revealed that the
background of Akt1Myr/KRasG12D mutant mice was ~60% C57Bl/6N.
Genotype Analysis
Reactions were assembled using JumpStart REDTaq ReadyMix
(Sigma, St Louis, MO). Primers for polymerase chain reaction (PCR)
detected presence of Pdx-Cre (5′-ATCGCTGATTTGTGTAGTC
GGT-3′; 5′-CAACAGTTGCGCAGCCTGAATG-3′), mutant or
non-recombined LSL-KRasG12D (5′-GTCGACAAGCTCATGC
GGGTG-3′ ; 5′-AGCTAGCC-ACCATGGCTTGAGTAC
GTCTGCA-3′; 5′-CCTTTACAAGCGCACGCA-GACTGTAGA-
3′), heterozygous knock-in for tTA into the endogenous Pdx gene (5′-
ACCATGAACAGTGAGGAGCAGTAC-3′; 5′-GCGGGTTTCA-
GAGGAATTTGT-3′; 5′-TAGAAGGGGAAAGCTGGCAAG-3′; 5′-
TCCAGATCGAAATCGTCTAGCG-3′), or presence of TetO-Myr-
Akt1 (5′-CTGGACTACTTGCACTCCGAGAAG-3′ ; 5′-
CTGTGTAGGGTCCTTCTTGAGCAG-3′).
Histologic Analysis
Specimens were fixed in 10% neutral buffered formalin (Surgipath
Leica, Buffalo Grove, IL) and paraffin embedded. Five-micrometer
sections were cut with a rotary microtome (Leica). Histologic staining
used SelecTech hematoxylin and eosin (H&E) reagents (Surgipath).
Staining with Alcian Blue or Trichrome (both from American
MasterTech, Lodi,CA)was performed as permanufacturers' instructions.
Antigen retrieval for immunohistochemistrywas optimizedwith sodium
citrate (pH 6.0) or EDTA (pH9.0; Leica). Primary antibodies were against
phospho-Akt Ser473 (GeneTex, Irvine, CA), phospho-mTor Ser2448
(Cell Signaling Technology, Danvers, MA), phospho-p70S6K Thr389
(Upstate Cell Signaling, Temecula, CA or LifeSpan BioSciences, Seattle,
WA), and phospho-p70S6K Thr389 (Cell Signaling Technology), mucin-
4 (Muc-4; LifeSpan BioSciences), α-2 smooth muscle actin (α-SMA;
Novus, Littleton, CO), cytokeratin 17/19 (Cell Signaling Technology),
and Ki67 (Abcam, Cambridge, MA). Detection used Polymer Refine
Detection reagents (Leica). A Bond-Max Immunostainer and Polymer
Refine Detection reagents (Leica) were used.
Cell Culture
Primary cells were collected following the killing of mice, and
cells were derived fromphosphate-buffered saline–washed peritoneum and
cultured using Dulbecco's modified Eagle's medium (Cellgro Mediatech,
Manassas, VA) supplemented with 15% FBS, 2 mM L-glutamine, and
2 mM penicillin-streptomycin. Murine pancreatic cell cultures were
maintained in Dulbecco's modified Eagle's medium/10% FBS supple-
mented with 2 mM L-glutamine and penicillin-streptomycin. Human cell
lines were from American Type Culture Collection (Manassas, VA) and
grown as recommended.
Genomic PCR
Genomic DNA was extracted (Wizard Genomic DNA Isolation
Kit; Promega), and PCRs were performed with GoTaq Green Master
Figure 1. Tumor latency in Akt1Myr/KRasG12D versus KRasG12D mice.
Akt1Myr/KRasG12D mice (broken line) developed pancreatic tumors
(PDACs) at a faster rate than KRasG12D mice (solid line). Curves were
significantly different with a P value b .0001 by log rank (Mantel-Cox)
or Gehan-Breslow-Wilcoxon tests (GraphPad Prism 5).
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CTTGACACCTGATCGTTACTC-3′ and 5′-CAGTCCTAACCC
CACAGGCGG-3 ′ ) , p16Ink4a (5 ′ -TGGTCACACGAC
TGGGCGATTG-3′ and 5′-GAATCGGGGTACGACCGAAAG-3′),
p19Arf (5′-AGCATGGGTCGCAGGTTCTTGG-3′ and 5′-
TTGAGGAGGACCGTGAAGCCGA-3′), and control glyceraldehyde
3-phosphate dehydrogenase or Gapdh (5′-AGGCCGGTGCTGAG-
TATGTC-3′ and 5′-TGCCTGCTTCACCACCTTCT-3′).
Western Blots
Whole-cell extracts were harvested from low passage cell cultures
with 1× cell lysis buffer (Cell Signaling Technology) for protein, 1 mM
phenylmethylsulfonyl fluoride (Sigma), and 2 mM Halt protease and
phosphatase inhibitor cocktail (Thermo, Waltham, MA). Protein was
quantified using the Bradfordmethod. ForWestern blot analysis, 60 μg
of each protein extract was combined with Laemmli's sodium dodecyl
sulfate sample buffer (final 1×) and denatured in a boiling water bath for
5minutes. Precision Plus (Bio-Rad Laboratories, Hercules, CA) protein
standard and total protein were separated on 12% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis gels using a Mini-Protean
Tetra Cell (Bio-Rad) unit set for 15 minutes at 20 mA and then 1 hour
at 40 mA constant current. Proteins were transferred to Hybond ECL
Nitrocellulose (GE Healthcare Amersham, Pittsburgh, PA) at 25 V at
4°C for 2 hours using an XCell II Blot Module (Invitrogen Life
Technologies, Grand Island, NY). Antibodies for Western blots were
against total Akt, phospho-Akt Ser473, and p53 (all fromCell Signaling
Technology),mouse p16Ink4a (Santa Cruz Biotechnology, Santa Cruz,
CA), mouse p19Arf (Abcam), and actin (Millipore, Billerica, MA).
Secondary antibodies were anti-mouse (DyLight, Thermo) and anti-
rabbit (IR Dye; LI-COR Biosciences, Lincoln, NE), and signals were
visualized using an Odyssey Infrared Imaging System (LI-COR).
Results
Accelerated Frequency of PDACs in Double Mutant Mice
Compared to Single Mutant Mice
The pancreatic tumor model uses the Pdx1 pancreas promoter to
drive expression of myristoylated, membrane-targeted, and therefore
activated Akt. Specifically, it uses a dual transgenic system with
tetracycline operator (TetO) sequences fused to MyrAkt1 [15–17], and
then the progeny were crossed with Pdx-TetA (Pdx-tTA) knock-in mice
expressing tTA in the pancreas [14]. Resultant Pdx-tTA;TetO-MyrAkt1
transgenic mice were identified by genotyping (Figure S1).
Transgenic Lox-Stop-Lox (LSL) KRasG12D [3] and Pdx-Cre [4] mice
were expanded, and these parental mice were mated to obtain compound
mice expressing Pdx-Cre–activated KRasG12D. Resultant Pdx-Cre;LSL-
KRasG12D were then mated to Pdx-tTA;TetO-MyrAkt1 mice to generate
pancreatic-specific active mutant KRasG12D, active MyrAkt1, compound
mutant Akt1Myr/KRasG12D mice or non-mutant littermates. The progeny
were genotyped and littermates were followed phenotypically to determine
if there is cooperation between mutant active KRasG12D and MyrAkt1 to
accelerate malignancy and/or metastasis and to establish a potentially
clinically relevant pancreatic tumor model useful for future preclinical
studies to test novel targeted therapies.
Figure 1 shows age in weeks when a carcinoma was detected in mice
with compound Akt1Myr/KRasG12D relative to mice with KRasG12D
mutant alone. Kaplan-Meier curves (GraphPad Prism 5, San Diego,
CA) were used to calculate median tumor detection at 54 weeks in
Akt1Myr/KRasG12D mice compared to 74 weeks in KRasG12D mice.
At the median 54-week time point for Akt1Myr/KRasG12D mice, 11 of22 mice examined had developed early to full pancreatic carcinoma. In
comparison, only one early carcinoma and one PDAC were found
in seven age-matched KRasG12D mice, and tumor progression to
PDAC was significantly delayed in a subset of KRasG12D mice until
approximately 15 months of age. Overall, the number of mice found
with early carcinoma to PDAC was 14 of 30 Akt1Myr/KRasG12D and
13 of 29 KRasG12D mice, even though Akt1/KRasG12D mice declined
in health earlier and could not be aged as far as KRasG12D mice. Four
metastatic tumors were found in Akt1Myr/KRasG12D mice at 8 to 12
months of age compared to 0metastatic tumors in KRasG12D (Table 1).
In contrast, littermates that were Akt1Myr mice had a tendency to
develop islet carcinomas (Figure S2), rather than ductal carcinomas, at a
mean latency of 75 weeks in 6 of 24 mice. Because of the predominant
islet carcinoma lineage in the Akt1Myr subset, these mice were not
characterized further in the context of this PDAC study.
Double Akt1Myr/KRasG12D Mice at ≤1 Year of Age Exhibit
PanINs and PDACs
In a separate experiment, compound mutant Akt1Myr/KRasG12D
mice were then studied within 12 months for the frequency of PanINs
andmetastatic PDACs.Nearly 77%of compoundAkt1Myr/KRasG12Dmice
aged ≤1 year exhibited high-grade PanINs and or PDACs (Table 2). Four of
17 mice developed PDACs. This is consistent with the results from the
Kaplan-Meier study,which showedmedianhistologic detection ofmalignant
tumor progression at 54 weeks in Akt1Myr/KRasG12D mice (Figure 1).
Akt Pathway Effector Proteins Are Activated in Early PanINs
and Metastatic PDACs
Immunohistochemistry using phosphorylation-specific antibodies
depicted abundant Akt pathway signaling in PanINs and metastatic
PDACs (Figure 2). Pathway markers, including phospho-Akt, phospho-
mTor, and phospho-p70S6 kinase were found in the pancreas of both
Akt1Myr/KRasG12D (Figure 2A) and KRasG12D mice (Figure 2B). A
possible mechanism may be increased proliferation, as detected by Ki67
staining, in the PanINs shown in Figure 2A (see Figure S3). Metastatic
PDACs in Akt1Myr/KRasG12D mice exhibited ascites and metastasis to
liver or other abdominal sites, with abundant levels of phospho-Akt and
elevated levels of phospho-mTor and phospho-p70S6 kinase at the
metastatic sites (Figure 2C).
Table 1. Mice with Pancreatic Carcinomas for Kaplan-Meier Analysis
b8 Months 8 to16 Months N16 Months Total
Akt1Myr/KRasG12D 1/6 mice 12/23
mice
(four metastases)
1/1 mouse
(0 metastasis)
14/30
KRasG12D 5/14 mice
(0 metastasis)
8/15 mice
(two metastases)
13/29 †
Akt1Myr/KRasG12D mice were collected at b8 months primarily because of weight loss, although
KRasG12D mice did not exhibit comparable issues.
† Other pathologies in aged KRasG12D mice ≥12 months of age included lymphomas, hepatocellular carcinoma,
and lung adenocarcinoma; a lung adenocarcinoma was found in an aged-matched Akt1Myr/KRasG12D mouse.
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Undergoing Progression to PDAC
Alcian Blue and Muc-4 staining, markers of mucin expression,
were evident in the pancreatic ducts found in proximity to PDACs.
Importantly, Muc-4 is a mucin that has been implicated as a marker
of pancreatic ductal tissue transformation in human PanINs and
PDACs [18]. In mice, Muc-4 has also been shown to correlate with
the progression of pancreatic cancer from PanIN lesions to PDAC
[19]. Staining for Muc-4 was found in ductal regions, as well as some
acinar regions of Akt1Myr/KRasG12D mice with PDAC (Figure 3).
Similarly, activation of pancreatic stellate cells near centroacinar
cells has been implicated as contributing to desmoplastic or fibrotic
areas in PDACs and frequently expressesα-SMA [20]. Recurrent staining
for trichrome and α-SMA was found around the acinar regions of
pancreatic tissue with PDAC and PanIN lesions in Akt1Myr/KRasG12D
mice (Figure 3A, representative age 7 months) and KRasG12D mice
(Figure 3B, representative age 12months). Trichrome stain revealed mild
to moderate fibrosis, reminiscent of desmoplasia. Intensity of trichrome
stain was variable, as depicted by green-blue staining (Figure S4) in a 12-
month-old Akt1Myr/KRasG12D mouse. α-SMA staining was frequently
detected in pancreatic acini exhibiting a myoepithelial distribution
pattern.Table 2. Representative Histology of Akt1Myr/KRasG12D Mice up to 1 Year of Age
Mouse ID Genotype Age
(Weeks)
PanIN Low
Grade
PanIN High
Grade
PDAC
173 Akt1Myr/KRasG12D 13.6 X X
524 † Akt1Myr/KRasG12D 20.6 X
179 Akt1Myr/KRasG12D 27.7 X X X (papillary)
505 Akt1Myr/KRasG12D 29.1 X
547 Akt1Myr/KRasG12D 29.4 X X
192 Akt1Myr/KRasG12D 31.1 X X
195 (562) Akt1Myr/KRasG12D 31.1 X X X (papillary)
160 Akt1Myr/KRasG12D 31.9 X
161 Akt1Myr/KRasG12D 31.9 X X
165 Akt1Myr/KRasG12D 31.9 X X
139 Akt1Myr/KRasG12D 38.4 X
157 Akt1Myr/KRasG12D 46.4 X
533 Akt1Myr/KRasG12D 43.1 X X (metastasis,
carcinomatosis)
9C Akt1Myr/KRasG12D 46.4 X X (metastasis)
167 Akt1Myr/KRasG12D 48.4 X
106 Akt1Myr/KRasG12D 50.9 X X
177-2 Akt1Myr/KRasG12D 52.9 X
12 of 17 13 of 17 4 of 17
Fibroadenomatous lesions are also found in 173, 524, 547, 160, 161, 165, 157, 106, and 177-2.
† Cystic papillary lesion, early cystoadenoma, and intraductal papillary tumor are found in 524, 192,
and 167, respectively.Tumor Cells from Double Mutant Mice Exhibit High Akt
Phosphorylation and Loss of Tumor Suppressors Known to be
Important in Human Pancreatic Tumor Progression
Cell cultures were derived from three KRasG12Dmice diagnosed with
PanINs at age 10 to 11months and also three Akt1Myr/KRasG12D mice
with preneoplastic lesions and/or PDACs at age 7 to 11 months of age.
Western blot analysis revealed high levels of phosphorylated Akt in low
passage cell cultures from Akt1Myr/KRasG12D mice, relative to cells
fromKRasG12D mice and two human PDAC cell lines (Figure 4A). For
mouse tumors cells, p53 tumor suppressor protein was retained in all
cases. p16Ink4a protein expressionwas frequently downregulated in the cell
cultures, with complete loss of p16Ink4a in one of the Akt1Myr/KRasG12D
PDAC cell cultures. P19Arf protein expression was also difficult to detect,
and p19Arf protein was absent in the same PDAC cell culture with loss of
p16Ink4a. Genomic PCR confirmed biallelic loss of the overlapping genes
p16Ink4a and p19Arf, which reside at the Cdk2na locus, in tumor cells
from an Akt1Myr/KRasG12D mouse that developed PDAC (Figure 4B).
Such homozygous losses of CDNK2A are common in human PDACs.
Moreover, a tumorigenicity study with this same PDAC tumor cell culture
revealed that it was capable of forming tumors in syngeneic mice without
themutant alleles at ~3 weeks after the orthotopic injection of 1 × 106 cells
into mouse pancreas (Figure S5).Discussion
Pancreatic mouse models targeting genes known to be mapped to the
histologic and genetic profile of PDACs have been used to test cooperativity
with KRas mutations, as reviewed elsewhere [21]. In most cases, the
combination of the predisposing KRas mutation with loss of tumor
suppressors, such as p16Ink4a or p53, greatly accelerates malignancy such
that mice frequently die within a few months. In humans, according to
2014 American Cancer Society projections, the median age of pancreatic
cancer detection is 71 years old and increases with age (http://www.cancer.
org/acs/groups/content/@research/documents/document/acspc-038828.
pdf). Moreover, in humans, the progression of PanINs to PDAC probably
takes more than a decade to develop [22]. Thus, the rapid onset of
pancreatic disease in compound KRas/tumor suppressor knockout mice
has limited utility for studies relevant to disease in the elderly andwith other
non-genetic factors that contribute to disease and treatment. The overall
objective of the current in vivo study was to combine two oncogenic
changes important for cancer progression to accelerate tumorigenesis, while
maintaining a time frame that would align more closely with the
physiological progression observed in the human disease.
Recently, E17K mutations in the AKT1 pleckstrin homology
domain have been found in human pancreatic intraductal papillary
mucinous neoplasms (3 of 36), along with activatingmutations in PI3K
or loss of PTEN [23]. AKT1 E17K mutations were not found in a
previous study of PDACs [24], although the number of cases examined
(12) was small. Thus, the role of the AKT1 E17Kmutation is still being
defined and may be context dependent. As proof of principle, we used
an Akt1 construct with an N-terminal myristoylation sequence
(MyrAkt1), one of the oldest known constitutively active mutants of
Akt1 [25], to directly test the experimental in vivo role of constitutively
active Akt1Myr in the progression fromPanINs to PDAC. In contrast to
the E17Kmutation, the myristoylation sequence is well documented as
directing Akt to the plasma membrane and facilitating constitutive
activation [26], which in turn has been shown to be important for
oncogenic transformation [27].
In addition to active mutant AKT1, loss of the PTEN tumor
suppressor protein or constitutive activation of receptor-mediated or
Figure 2. Activation of the Akt/mTor/S6K pathway in pancreatic tumor progression. The panels show representative early ductal
pancreatic lesions, similar to human low-grade PanINs, with strong activation (brown DAB stain) for phospho-Akt, phospho-mTor, and
phospho-p70S6 kinase in PanINs of (A) Akt1Myr/KRasG12D and (B) KRasG12D mice (40× objective). (C) Immunohistochemical staining of
primary PDAC and metastatic specimens from a ~43-week-old Akt1Myr/KRasG12D mouse for phospho-Akt, phospho-mTor, and phospho-
p70S6 kinase and cytokeratin 17/19; a set of panels corresponding to PDAC metastasis to liver (10× objective and a scale bar
corresponding to 200 μm, with boxed-in close ups from the 40× objective and a scale bar of 50 μm). In the metastasis panels, L = liver
and T = tumor. Images were acquired using a Leica DM 2000 microscope with a digital DFC 295 camera.
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of AKT isoforms [28,29]. Moreover, it has been suggested that loss of
PTEN function and active mutations of KRas may converge to
facilitate tumor growth [30]. In terms of previous mouse models of
pancreatic cancer, it has been suggested that variations in phenotypes
between Pdx-Cre–activated KRasG12D and Pdx-Cre;Ptenlox/lox mice
may be attributed to differences in the relative expression of KRas and
Pten within centroacinar and duct cells. Previously, it was shown that
all mice with KRasG12D activation and Pten homozygous deletion
succumb to cancer by 3 weeks of age, and compound mutant mice for
KRasG12D and heterozygous for Pten lox/+ show accelerated acinar-to-
ductal metaplasia, PanINs, and PDAC within a year [13]. The high
levels of phosphorylated effectors downstream in the Pten/Akt
signaling cascade may be a mechanism to facilitate the ductal
pancreatic tumor progression. In addition, Pdx-Cre;Pten−/− pancre-
atic knockout mice were shown to display progressive replacement of
the acinar cells, with ductal structures that expressed mucins.6In the Akt1Myr/KRasG12D model presented here, tumor onset was
accelerated compared to that observed in the KRasG12D model. The
first Kaplan-Meier analysis showed that Akt1Myr/KRasG12D mice
aged 8 to 16 months had the greatest incidence of early or late
carcinomas (12/23 or 52% of the mice in this age group), with 4
metastatic tumors, compared to only 5 of 14 (35%) of the KRasG12D
mice (Figure 1 and Table 1). Overall, only two KRasG12D mice with
metastasis were found at N16 months of age when more tumors
were found in the KRasG12D group and at an age when only one
Akt1Myr/KRasG12D could be analyzed. The second Akt1Myr/KRasG12D
study used re-derived mice when the colony was transferred to a new
institution. It focused on mice aged to 1 year (Table 2) and was
consistent with the Kaplan-Meier analysis in finding PanINs and
PDAC, some with metastasis at less than 1 year of age. We cannot rule
out other factors that may contribute to the decline of health in the
Akt1Myr/KRasG12D mice, and these factors may come to light as we
start analyzing the role of the MyrAkt1 construct in facilitating tissue
Figure 3. Pancreatichistologicalterations inAkt1Myr/KRasG12DandKRasG12Dmice.Thepanels from(A)Akt1Myr/KRasG12Dand (B)KRasG12Dmiceshow
staining of representative pancreatic tissues. Sections showed staining for H&E, Alcian Blue staining of ducts for detection ofmucin (dark blue),Muc-4
(brown color) in areas of ducts, trichrome stain of red acinar cells, and green-blue collagen-rich fibrotic areas of the PDAC tumor and α-SMAmarker
(browncolor) inareasofacinarcellsnear fibrotic regions.Boxed-inhighlightedareas (10×objective,scalebarof200μm)weremagnified fora focal view
with the 40× objective (scale bar of 50 μm).
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future studies.
Here, we report that PDAC formation in the compound transgenic
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and acinar components, as evident by increased mucin, α-SMA, and
nearby fibrosis. Similar to other reports implicating Muc-4 as a marker
of pancreatic ductal tissue transformation in human PanINs and
PDACs [18], Muc-4 expression and overall Alcian Blue for both neural
and acidic mucins was increased in the ductal components in PanINs
and in focal regions of the PDACs in these mice (Figure 3). Similarly,
moderate to abundant collagen in the stroma was evident in disrupted
acinar regions and around abnormal ducts.
To examine common genetic changes that are known to be
important in the pancreatic tumor progression cascade, tumor cells
were derived from the mice predisposed to pancreatic tumor
progression and examined for down-regulation or occasional biallelic
loss of tumor suppressor genes commonly implicated in PDAC.
Overall, the establishment of cell cultures from the KRasG12D mice
was challenging, perhaps in part due to the inefficiency of developing
full PDACs until mice had reached an advanced age. A limited
number of primary cultures from Akt1Myr/KRasG12D PDACs were
established. Similar to human pancreatic tumors, genomic PCR and
Western blot analysis confirmed biallelic loss of p16Ink4a and p19Arf
tumor suppressor gene expression in representative PDAC cells from
an Akt1Myr/KRasG12D mouse (Figure 4). Moreover, staining for
H&E and immunohistochemistry against cytokeratin 17/19 detected
tumors fromAkt1Myr/KRasG12D PDACcells when theywere orthotopically
re-injected into the pancreas of a syngeneic mouse to show tumorigenic
potential (Figure S5).
Collectively, compound Akt1Myr/KRasG12D mice exhibited accel-
erated PDAC development compared with KRasG12D mice, and the
tumors in Akt1Myr/KRasG12D mice showed histologic and genetic
alterations that recapitulate those found in human pancreatic
progression. Thus, this mouse model is likely to be of importance
for preclinical testing of novel therapeutics targeting KRas and/or
PI3K/Akt signaling in pancreatic cancer. Future analysis of the
Akt1Myr/KRasG12D mouse model is expected to elucidate in vivo
contexts in which Akt1 and KRas oncogenes interact in the pancreatic
microenvironment to better facilitate treatment and overcome poor
patient prognosis currently associated with this deadly disease.
In particular, we suggest that the model may have added value for
chemoprevention studies to block tumor progression at the PanIN or
early carcinoma stage, perhaps before a stage where there is excessive
desmoplastic damage and fibrosis.
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